Market cap
$2,708 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
3.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -44.86 | 141.15 | -89.24 | -18.23 | -18.69 |
| EBIT | -16.92 | -95.75 | -237.68 | -383.55 | -23.54 |
| Net Profit | -11.25 | -77.82 | -162.71 | -328.77 | -139.55 |
| EPS | -9.86 | -53.95 | -104.84 | -315.71 | 2.42 |
| Book Value | -- | -- | -24.43 | -- | -4.16 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -3,337.01 | -2,159.71 | -4,288.12 | -3,020.28 | -191.84 |
| Net Margin
| -3,681.58 | -3,681.58 | -2,767.21 | -- | -203.34 |
| Return on equity
| -40.85 | -54.64 | -60.88 | -41.23 | -25.70 |
| Return on Capital
| -36.43 | -51.55 | -- | -37.71 | -23.18 |
| Return on Assets
| -29.85 | -27.69 | -41.50 | -32.45 | -20.41 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.09 | 0.10 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
--
|
-37.71
|
-23.18
|
-48.39
|
-97.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-60.88
Lower than Peers by 20.48
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-60.88
|
-41.23
|
-25.70
|
-55.62
|
-99.48
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-41.50
Lower than Peers by 10.52
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-41.50
|
-32.45
|
-20.41
|
-36.71
|
-25.11
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
-4,288.12
Lower than Peers by 4,204.50
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-4,288.12
|
-3,020.28
|
-191.84
|
-6,798.91
|
-115.69
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
-2,767.21
Lower than Peers by 2,674.54
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-2,767.21
|
-3,012.65
|
-203.34
|
-7,159.82
|
-271.47
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
-89.24
Lower than Peers by 143.19
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-89.24
|
-0.88
|
61.42
|
-0.95
|
0.14
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
-237.68
Lower than Peers by 236.89
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-237.68
|
-86.88
|
-76.14
|
-181.61
|
80.30
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
-162.71
Lower than Peers by 155.41
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-162.71
|
-82.24
|
-24.11
|
-74.22
|
50.87
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
-104.84
Lower than Peers by 119.49
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-104.84
|
-0.41
|
0.02
|
-0.32
|
0.51
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
-39.05
Lower than Peers by 28.87
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-39.05
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
--
|
0.09
|
0.10
|
0.12
|
-0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
0.01
|
0.01
|
0.01
|
0.01
|
-0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
5.82
Higher than Peers by 0.01
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
5.82
|
7.59
|
7.50
|
11.14
|
5.16
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
5.82
Higher than Peers by 0.12
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
5.82
|
--
|
10.12
|
--
|
6.39
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-19.64
Lower than Peers by 17.55
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-19.64
|
-25.78
|
-2.36
|
-3,748.47
|
-605.03
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
53.03
Higher than Peers by 33.89
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
53.03
|
17.80
|
19.49
|
31.68
|
1.98
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
0.01
Lower than Peers by 0.05
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
0.01
|
0.01
|
0.10
|
0.00
|
0.09
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
--
|
332.35
|
36.52
|
133.38
|
131.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
--
|
-22,295.31
|
-22,757.87
|
-2,572.33
|
-1,959.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
--
|
1,944.08
|
1,361.30
|
2,135.24
|
789.84
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
--
|
-23,907.04
|
-24,082.65
|
-4,574.19
|
-2,618.27
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
--
|
-9.82
|
-8.64
|
-8.22
|
-0.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
3.06
Lower than Peers by 2.13
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
3.06
|
4.10
|
1.93
|
2.00
|
-0.92
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-11.50
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
-11.50
|
-8.98
|
-11.07
|
-8.61
|
6.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
2,708
Higher than Peers by 2,562
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
2,708
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|